Zevra Therapeutics Files 2024 10-K
Ticker: ZVRA · Form: 10-K · Filed: Mar 12, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 10-K |
| Filed Date | Mar 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Zevra Therapeutics filed its 2024 10-K. Check financials.
AI Summary
Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed its 2024 10-K on March 12, 2025, reporting a fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, is headquartered in Celebration, Florida. The filing details its financial performance and business operations for the past fiscal year.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Zevra Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Zevra Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 250,000,000 — Authorized Shares (Indicates the maximum number of shares the company can issue.)
- 55,246,401 — Common Stock Issued (Represents the total number of common shares issued as of the fiscal year end.)
- 43,110,360 — Common Stock Outstanding (Shows the number of shares held by investors at the end of the fiscal year.)
- 10,615,385 — Warrants (Details outstanding warrants, which could impact future share count and dilution.)
Key Players & Entities
- ZEVRA THERAPEUTICS, INC. (company) — Filer
- KEMPHARM, INC (company) — Former Company Name
- CELEBRATION, FL (location) — Business Address City, State
- 20241231 (date) — Fiscal Year End
- 20250312 (date) — Filing Date
FAQ
What was Zevra Therapeutics' net income for the fiscal year ended December 31, 2024?
The provided excerpt does not explicitly state the net income for the fiscal year ended December 31, 2024. It lists figures for common stock issued and outstanding, but not profitability.
What is the company's primary business activity?
Zevra Therapeutics, Inc. is involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When did the company change its name from KemPharm, Inc.?
The company's name was changed from KEMPHARM, INC on May 30, 2013.
What is the company's principal executive office address?
The company's business address is 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
How many documents are included in this 10-K filing?
This 10-K filing includes a total of 117 documents.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 12, 2025 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).